AskBio Inc
12
3
7
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)
Role: lead
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease
Role: collaborator
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
Role: lead
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Role: lead
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Role: lead
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
Role: lead
Prescriptive Infusion Algorithm (PIA)
Role: lead
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Role: lead
AB-1005 Long-Term Follow-up Study
Role: lead
GDNF Gene Therapy for Parkinson's Disease
Role: collaborator
AB-1002 in Patients With Class III Heart Failure
Role: lead
Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy
Role: collaborator
All 12 trials loaded